Literature DB >> 25824865

Hospitalization rates and utilization among patients with giant cell arteritis: A population-based study from 1987 to 2012.

Clement John Michet1, Sara J Achenbach2, Cynthia S Crowson3, Eric L Matteson4.   

Abstract

BACKGROUND: Patients with giant cell arteritis (GCA) may experience serious vascular and visual complications. It is unknown, however, to what extent the difficulties of the disease may lead to hospitalization. The goal of this study is to discern whether patients with GCA are at greater risk for all-cause hospitalizations when compared to the general population.
METHODS: This retrospective, population-based cohort study utilized patients with large vessel or visual involvement who were diagnosed with GCA (as defined by the 1990 ACR criteria) between 1/1/1950 and 12/31/2009, and a reference cohort of patients without GCA matched on age, sex, and calendar year. Each patients' medical record was examined for hospitalizations from 1987 through 2012. For this analysis, follow-up began with the latter of index date or 1/1/1987 and ended at the earlier of death, emigration from Olmsted County, or 12/31/2012. Discharge diagnoses were grouped together using the Clinical Classifications Software (CCS) for ICD-9-CM from Healthcare Cost and Utilization Project (HCUP). Data were analyzed using person-year methods and rate ratios comparing GCA to non-GCA.
RESULTS: The GCA cohort consists of 199 patients with a mean age of 76.2 (79.9% female) and follow-up of 8.2 years. The non-GCA cohort is comprised of 194 patients with a mean age of 75.7 (78.9% female) and follow-up of 8.6 years. The patients with GCA had 816 hospitalizations and the non-GCA patients had 737 hospitalizations. GCA patients proved to be at a marginally greater risk for all causes of hospitalization [rate ratio (RR) = 1.13; 95% confidence interval (CI): 1.02-1.25]; however, the rate of hospitalization for patients with and without GCA decreased significantly from 1987 to 2012. Two specific discharge categories are of interest. First, transient cerebral ischemia is a greater risk of hospitalization for patients with GCA who had 16 hospitalizations compared to patients without GCA who only had 5 hospitalizations (RR = 3.06; 95% CI: 1.27-9.47). Second, patients with GCA (21 hospitalizations) are at greater risk of hospitalization for syncope than patients without GCA (5 hospitalizations) (RR = 3.98; 95% CI: 1.72-12.14).
CONCLUSION: In this first ever analysis of all-cause hospitalizations in a population-based cohort, patients with GCA appear to be at a marginally greater risk for hospitalization than patients without GCA, although the rate of hospitalization for GCA patients decreased from 1987 to 2012. Patients with GCA are at increased risk of hospitalization for both transient cerebral ischemia and syncope.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Giant cell arteritis; Health utilization; Hospitalization

Mesh:

Year:  2015        PMID: 25824865      PMCID: PMC4515376          DOI: 10.1016/j.semarthrit.2015.02.010

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  22 in total

1.  Temporal arteritis in Vest Agder County in southern Norway: incidence and clinical findings.

Authors:  G Haugeberg; P Q Paulsen; R B Bie
Journal:  J Rheumatol       Date:  2000-11       Impact factor: 4.666

2.  Cancer risk in patients hospitalized with polymyalgia rheumatica and giant cell arteritis: a follow-up study in Sweden.

Authors:  Jianguang Ji; Xiangdong Liu; Kristina Sundquist; Jan Sundquist; Kari Hemminki
Journal:  Rheumatology (Oxford)       Date:  2010-03-18       Impact factor: 7.580

3.  Increase in age at onset of giant cell arteritis: a population-based study.

Authors:  Tanaz A Kermani; Valentin S Schäfer; Cynthia S Crowson; Gene G Hunder; Sherine E Gabriel; Eric L Matteson; Kenneth J Warrington
Journal:  Ann Rheum Dis       Date:  2009-10-22       Impact factor: 19.103

4.  Statin use in giant cell arteritis: a retrospective study.

Authors:  Jean Schmidt; Tanaz A Kermani; Francesco Muratore; Cynthia S Crowson; Eric L Matteson; Kenneth J Warrington
Journal:  J Rheumatol       Date:  2013-04-01       Impact factor: 4.666

5.  Prevalence of diabetes mellitus in biopsy-positive giant cell arteritis.

Authors:  Jared L Matthews; David N Gilbert; Bradley K Farris; R Michael Siatkowski
Journal:  J Neuroophthalmol       Date:  2012-09       Impact factor: 3.042

6.  Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca
Journal:  Am J Epidemiol       Date:  2011-03-23       Impact factor: 4.897

7.  Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis.

Authors:  Tanaz A Kermani; Kenneth J Warrington; Cynthia S Crowson; Steven R Ytterberg; Gene G Hunder; Sherine E Gabriel; Eric L Matteson
Journal:  Ann Rheum Dis       Date:  2012-12-19       Impact factor: 19.103

8.  Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a Danish county. A prospective investigation, 1982-1985.

Authors:  P Boesen; S F Sørensen
Journal:  Arthritis Rheum       Date:  1987-03

9.  Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950-1985.

Authors:  E B Machado; C J Michet; D J Ballard; G G Hunder; C M Beard; C P Chu; W M O'Fallon
Journal:  Arthritis Rheum       Date:  1988-06

Review 10.  History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population.

Authors:  Walter A Rocca; Barbara P Yawn; Jennifer L St Sauver; Brandon R Grossardt; L Joseph Melton
Journal:  Mayo Clin Proc       Date:  2012-11-28       Impact factor: 7.616

View more
  5 in total

1.  Healthcare Use and Direct Cost of Giant Cell Arteritis: A Population-based Study.

Authors:  Matthew J Koster; Sara J Achenbach; Cynthia S Crowson; Hilal Maradit-Kremers; Eric L Matteson; Kenneth J Warrington
Journal:  J Rheumatol       Date:  2017-05-01       Impact factor: 4.666

2.  Does low risk of infections as a marker of effective immunity predict increased risk of subsequent giant cell arteritis or polymyalgia rheumatica? A Danish population-based case-control study.

Authors:  Clément Brault; Anders H Riis; Anil Mor; Pierre Duhaut; Reimar W Thomsen
Journal:  Clin Epidemiol       Date:  2018-10-16       Impact factor: 4.790

3.  Hospitalization Rates Are Highest in the First 5 Years of Systemic Sclerosis: Results From a Population-based Cohort (1980-2016).

Authors:  Caitrin M Coffey; Avneek S Sandhu; Cynthia S Crowson; Sara J Achenbach; Eric L Matteson; Thomas G Osborn; Kenneth J Warrington; Ashima Makol
Journal:  J Rheumatol       Date:  2020-11-15       Impact factor: 5.346

4.  Incidence of giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study.

Authors:  L K Brekke; A P Diamantopoulos; B-T Fevang; J Aβmus; E Esperø; C G Gjesdal
Journal:  Arthritis Res Ther       Date:  2017-12-15       Impact factor: 5.156

5.  Non-steroidal Anti-inflammatory Drug Use and Risk of Age-Related Macular Degeneration in the California Teachers Study.

Authors:  Xiaoqing Xu; Beate Ritz; Anne L Coleman; Zeyan Liew; Dennis Deapen; Eunjung Lee; Leslie Bernstein; Rich Pinder; Sarah F Marshall; Julia E Heck
Journal:  Drugs Aging       Date:  2021-07-26       Impact factor: 3.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.